LONDON, UK I October 20, 2014 I Mucosis B.V., a clinical stage biotechnology company using a proprietary technology platform to develop next-generation needle-free human vaccines for infectious diseases, will present research on its lead intranasal vaccine candidate SynGEM®, a vaccine candidate being researched to prevent infection with respiratory syncytial virus (RSV), at Vaccines 2014, taking place in London from 20-22 October.
SynGEM® uses Mucosis’s proprietary Mimopath® platform to activate mucosal defenses, allowing more effective protection against infectious diseases. The data presented will include updates on the development of Mucosis’s unique stable prefusion form of the F vaccine antigen, effective against RSV particularly due to the powerful virus neutralizing antibodies it elicits. Results from preclinical studies of SynGEM® in animal models will also be included.
Dr. Kees Leenhouts, Chief Scientific Officer of Mucosis said “We are excited to offer an insight into progress with our lead product, SynGEM®, after the success we’ve achieved in progressing our Mimopath® platform to clinical trial stage. Our prefusion F antigen construct, used in SynGEM®, is potentially able to generate antibodies 40-600 times more potent in virus neutralization compared to the current RSV treatment used in infants. Our new data, demonstrating the vaccine’s immunogenicity, efficacy and safety in animal models, supports the prophylactic potential of SynGEM® across the various target age groups and confirms the value of the unique and stable prefusion-like F form of the antigen we have developed.”
Thomas Johnston, Chief Executive Officer of Mucosis commented, “This is an excellent opportunity to present the evidence behind the breakthroughs we are making in treating infectious diseases. Our advances in both the delivery mechanism and efficacy of RSV vaccines are setting Mucosis apart in this competitive market.”
“SynGEM®: An intranasal prefusion-like RSV F subunit vaccine,” authored by Bert Jan Haijema, Maarten van Roosmalen, Ivy Widjaja, Alan Rigter of Mucosis, Xander de Haan, Peter Rottier of Utrecht University and Kees Leenhouts, will be presented by Dr. Leenhouts, at Vaccines 2014 today.
-Ends-
Note for Editors
About Mucosis www.mucosis.com
Mucosis B.V. (Mucosis) is a clinical-stage biotechnology company using a proprietary technology platform to develop next-generation needle-free human vaccines for infectious diseases. Mucosis’s investigational patient-friendly vaccines can be delivered via the nose or mouth to elicit a more natural immune response with a broader base of protection. The company is developing multiple programs for its clinical-stage proprietary Mimopath® platform vaccine technology for several routes of administration including those that provide additional mucosal protection, where over 90% of pathogens enter the human body.
Mucosis’s lead product SynGEM®, a stabilized recombinant vaccine delivered intranasally to prevent respiratory syncytial virus (RSV) infection, will enter human proof-of-concept studies in 2016. The annual global burden of RSV illness is significant, with 33.8 million estimated new episodes of RSV-associated acute lower respiratory infection (ALRI) worldwide in children under 5, and over3.4 million hospital admissions associated with severe RSV disease. Global mortality was estimated at 253,500 deaths in 2010.
The company has also developed PneuGEM®, a vaccine to prevent diseases caused by pneumococcal bacteria, and FluGEM®, a vaccine against influenza. FluGEM® served as a successful proof of concept for the Mimopath® platform in human clinical testing.
Mucosis has raised over EUR 20m, with key investment partners including MedSciences, BioGeneration, NOM & UU Holdings. The company has strategic partnerships in US, Asia and the EU with organisations including the US National Institutes of Health, China-based Changchun BCHT Biotechnology co., and the Netherlands Enterprise Agency. Mucosis’s management is highly experienced in the design, development and commercialisation of vaccines. Mucosis employs over 10 staff at its headquarters in Groningen, The Netherlands.
SOURCE: Mucosis
Post Views: 245
LONDON, UK I October 20, 2014 I Mucosis B.V., a clinical stage biotechnology company using a proprietary technology platform to develop next-generation needle-free human vaccines for infectious diseases, will present research on its lead intranasal vaccine candidate SynGEM®, a vaccine candidate being researched to prevent infection with respiratory syncytial virus (RSV), at Vaccines 2014, taking place in London from 20-22 October.
SynGEM® uses Mucosis’s proprietary Mimopath® platform to activate mucosal defenses, allowing more effective protection against infectious diseases. The data presented will include updates on the development of Mucosis’s unique stable prefusion form of the F vaccine antigen, effective against RSV particularly due to the powerful virus neutralizing antibodies it elicits. Results from preclinical studies of SynGEM® in animal models will also be included.
Dr. Kees Leenhouts, Chief Scientific Officer of Mucosis said “We are excited to offer an insight into progress with our lead product, SynGEM®, after the success we’ve achieved in progressing our Mimopath® platform to clinical trial stage. Our prefusion F antigen construct, used in SynGEM®, is potentially able to generate antibodies 40-600 times more potent in virus neutralization compared to the current RSV treatment used in infants. Our new data, demonstrating the vaccine’s immunogenicity, efficacy and safety in animal models, supports the prophylactic potential of SynGEM® across the various target age groups and confirms the value of the unique and stable prefusion-like F form of the antigen we have developed.”
Thomas Johnston, Chief Executive Officer of Mucosis commented, “This is an excellent opportunity to present the evidence behind the breakthroughs we are making in treating infectious diseases. Our advances in both the delivery mechanism and efficacy of RSV vaccines are setting Mucosis apart in this competitive market.”
“SynGEM®: An intranasal prefusion-like RSV F subunit vaccine,” authored by Bert Jan Haijema, Maarten van Roosmalen, Ivy Widjaja, Alan Rigter of Mucosis, Xander de Haan, Peter Rottier of Utrecht University and Kees Leenhouts, will be presented by Dr. Leenhouts, at Vaccines 2014 today.
-Ends-
Note for Editors
About Mucosis www.mucosis.com
Mucosis B.V. (Mucosis) is a clinical-stage biotechnology company using a proprietary technology platform to develop next-generation needle-free human vaccines for infectious diseases. Mucosis’s investigational patient-friendly vaccines can be delivered via the nose or mouth to elicit a more natural immune response with a broader base of protection. The company is developing multiple programs for its clinical-stage proprietary Mimopath® platform vaccine technology for several routes of administration including those that provide additional mucosal protection, where over 90% of pathogens enter the human body.
Mucosis’s lead product SynGEM®, a stabilized recombinant vaccine delivered intranasally to prevent respiratory syncytial virus (RSV) infection, will enter human proof-of-concept studies in 2016. The annual global burden of RSV illness is significant, with 33.8 million estimated new episodes of RSV-associated acute lower respiratory infection (ALRI) worldwide in children under 5, and over3.4 million hospital admissions associated with severe RSV disease. Global mortality was estimated at 253,500 deaths in 2010.
The company has also developed PneuGEM®, a vaccine to prevent diseases caused by pneumococcal bacteria, and FluGEM®, a vaccine against influenza. FluGEM® served as a successful proof of concept for the Mimopath® platform in human clinical testing.
Mucosis has raised over EUR 20m, with key investment partners including MedSciences, BioGeneration, NOM & UU Holdings. The company has strategic partnerships in US, Asia and the EU with organisations including the US National Institutes of Health, China-based Changchun BCHT Biotechnology co., and the Netherlands Enterprise Agency. Mucosis’s management is highly experienced in the design, development and commercialisation of vaccines. Mucosis employs over 10 staff at its headquarters in Groningen, The Netherlands.
SOURCE: Mucosis
Post Views: 245
